Among 494 patients who had undergone randomization, overall survival was significantly longer with trastuzumab deruxtecan than with ramucirumab plus paclitaxel (median, 14.7 vs. 11.4 months ...

Producing paclitaxel from the yew trees would be a considerable environmental burden. Moreover, the complicated structure of the molecule didn’t yield to organic synthesis easily.

Paclitaxel Mortality No Longer the Main Question. After years of being the standard drug for DCBs in PAD treatment, a safety signal for paclitaxel emerged in 2018 from a meta-analysis that led to a ...

Paclitaxel, often sold under the brand name Taxol, is one of the most widely prescribed chemotherapy drugs and is used to treat a variety of cancers, including breast, ovarian, and lung.

Golden Biotechnology has shared updated data on its mushroom-derived drug candidate in metastatic pancreatic cancer, linking first-line use of the molecule to median overall survival (OS) of 14.1 ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig in combination with paclitaxel in patients with unresectable advanced, metastatic or recurrent biliary tract cancers (BTC).

The primary patency rates between sirolimus- and paclitaxel-treated patients at 12 months showed a difference of just 1.2%, with a P value for noninferiority of 0.022, Ulf Teichgräber, MD, (University ...

The statement comes 4 years after the agency's first warnings of a mortality risk from paclitaxel-based peripheral stents and balloons, the controversy ignited by a 2018 meta-analysis.